{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:42:47Z","timestamp":1761237767935,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":905,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.rmed.2010.10.021","type":"journal-article","created":{"date-parts":[[2010,12,9]],"date-time":"2010-12-09T10:21:39Z","timestamp":1291890099000},"page":"337-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients"],"prefix":"10.1016","volume":"105","author":[{"given":"Charles","family":"Fogarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilla","family":"Di Scala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Drollmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","key":"10.1016\/j.rmed.2010.10.021_bib1"},{"key":"10.1016\/j.rmed.2010.10.021_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1183\/09031936.00082507","article-title":"Definition, epidemiology and natural history of COPD","volume":"30","author":"Viegi","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.10.021_bib3","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1378\/chest.120.4.1253","article-title":"Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD","volume":"120","author":"Taylor","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.10.021_bib4","first-page":"159","article-title":"Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients","volume":"47","author":"Cuvelier","year":"2002","journal-title":"Respir Care"},{"key":"10.1016\/j.rmed.2010.10.021_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thorax.55.4.289","article-title":"A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group","volume":"55","author":"Van Noord","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.10.021_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.10.021_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjp.0702573","article-title":"Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways","volume":"127","author":"Haddad","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.rmed.2010.10.021_bib8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.rmed.2010.04.006","article-title":"Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients","volume":"104","author":"Verkindre","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.10.021_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.pupt.2010.04.005","article-title":"Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients","volume":"23","author":"Vogelmeier","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","key":"10.1016\/j.rmed.2010.10.021_bib10"},{"key":"10.1016\/j.rmed.2010.10.021_bib11","first-page":"683","article-title":"Concept1 (a new single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients","volume":"3","author":"Pavkov","year":"2008","journal-title":"Resp Drug Deliv"},{"key":"10.1016\/j.rmed.2010.10.021_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1183\/09031936.05.00140404","article-title":"Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD","volume":"26","author":"van Noord","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.10.021_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr\u2019s treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.10.021_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/cs0690251","article-title":"Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction","volume":"69","author":"Postma","year":"1985","journal-title":"Clin Sci"},{"key":"10.1016\/j.rmed.2010.10.021_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0034-5687(77)90100-1","article-title":"Circadian rhythms in lung resistance and dynamic lung compliance of healthy children. Effects of two bronchodilators","volume":"31","author":"Gaultier","year":"1977","journal-title":"Respir Physiol"},{"key":"10.1016\/j.rmed.2010.10.021_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.CIR.81.2.537","article-title":"Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects","volume":"81","author":"Furlan","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.rmed.2010.10.021_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmed.2010.10.021_bib18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/thx.2006.063271","article-title":"Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis","volume":"61","author":"Barr","year":"2006","journal-title":"Thorax"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611110004725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611110004725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:04:44Z","timestamp":1760612684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611110004725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0954611110004725"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2010.10.021","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2010.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}